ライフサイエンスコーパス: EMD

1 EMD + NBM-treated defects showed a mean CAL change from

2 EMD 57033-binding protects myosin against heat stress an

3 EMD also enhanced (by 20% to 40%) the expression of tran

4 EMD also stimulated release of growth factors and cytoki

5 EMD and P2 promoted reepithelialization and neovasculari

6 EMD and P2 significantly promoted early wound closure at

7 EMD gel adsorbed less protein to the surface of grafting

8 EMD had an effect on levels of cytokines related to fibr

9 EMD had no effect on the epithelial gap of the wound.

10 EMD has specific, differential actions on PMNs that sugg

11 EMD improves oral mucosa incisional wound healing by pro

12 EMD induced a concentration-dependent increase of CTGF p

13 EMD maintained a significant acceleration of reepithelia

14 EMD may provide greater DF compared to non-treated contr

15 EMD may provide greater DF under diabetic or normal cond

16 EMD or TGF-beta1 provoked a significant increase of IL-1

17 EMD provided an increased defect fill (DF) in G1 and hig

18 EMD provided an increased DF in both groups and enhanced

19 EMD provides highest levels of CRC; however, the additio

20 EMD significantly increased cell proliferation at 3 and

21 EMD significantly increased PMN chemotactic activity (P

22 EMD stimulates angiogenesis in the CAM model.

23 EMD stimulates CTGF expression in human PDL cells, a pro

24 EMD treatment predictably alters a dysbiotic subgingival

25 EMD+CAF continues to show histologic evidence of periodo

26 EMD- and TGF-beta1-stimulated CTGF expression was signif

27 The present results suggest that 1) EMD enhances osteoblast and PDL cell attachment, prolife

28 On both days 5 and 9, EMD treatment increased significantly the number of bloo

29 CTGF can affect EMD- and TGF-beta1-induced PDL cell proliferation, but i

30 vention groups: ortho/EMD/DFDBA (n = 24) and EMD/DFDBA (n = 23).

31 differences among control, blood-coated, and EMD-coated DFDBA particles.

32 The effect of CTGF and EMD on osteoblastic mRNA expression in PDL cells is not

33 SCTGs, matrix grafts, and EMD were superior to CAF in achieving CRC, but SCTGs sho

34 Merck Serono (Merck KGaA) and EMD Serono (Merck KGaA).

35 that the combination of EMD liquid + NBM and EMD liquid + DFDBA adsorbed higher amounts of amelogenin

36 0.63 +/- 0.42 mm) compared with the OFD and EMD groups (P <0.05).

37 -resolution immunocytochemistry with an anti-EMD antibody.

38 nd immunohistochemical staining with an anti-EMD antibody.

39 munostaining assay with gold-conjugated anti-EMD antibody.

40 In univariable analysis, the presence of any EMD ( P = .005), skin involvement ( P = .002), spleen (

41 This investigation compares applying EMD in solution to cells with precoating of wells with E

42 ur, which was similar to adjacent tissues at EMD-treated sites but greater than adjacent tissues at a

43 non-contained defects may be limited because EMD does not maintain a space itself.

44 tatistically significant differences between EMD + CAF and CTG + CAF for any measured parameter.

45 the frequency of residual PD >/=6 mm between EMD + DBBM (5%) and CM + DBBM (15%) (P = 0.21).

46 ng the frequency of CAL gain >/=4 mm between EMD + DBBM (60%) and CM + DBBM (50%) or comparing the fr

47 However, EMD and BONE+EMD groups demonstrated more long-term reductions in a h

48 CTGF inhibition downregulated both EMD- and TGF-beta1-induced DNA synthesis.

49 Esthetically, both EMD- and CTG-mediated treatments were similar at 10 year

50 No cytotoxic effects caused by EMD were detected.

51 urthermore, amelogenin proteins delivered by EMD liquid were able to penetrate the porous surface str

52 ver, the anti-inflammatory effect induced by EMD observed in the in vitro study could not be confirme

53 f the epithelial barrier function induced by EMD were investigated by analysis of transepithelial ele

54 n stimulation was significantly inhibited by EMD (P <0.05).

55 atrial natriuretic peptide is suppressed by EMD 57033.

56 Wounds treated by EMD and P2 showed increased angiogenesis during the firs

57 with CAF (n = 17), CAF + CM (n = 17), CAF + EMD (n = 17), and CAF + CM + EMD (n = 17).

58 ither CAF (n = 17); CAF + CM (n = 17); CAF + EMD (n = 17), or CAF + CM + EMD (n = 17).

59 6 months was significant for CAF + CM, CAF + EMD, and CAF + CM + EMD (P <0.05).

60 tients with GRs treated with CAF + CM, CAF + EMD, and CAF + CM + EMD.

61 Complete root coverage (CRC) for CAF + EMD was 70.59%, significantly superior to CAF alone (23.

62 A small molecule called EMD 57033 can repair motor proteins that have stopped wo

63 he choice, six of nine patients would choose EMD over CTG treatment to avoid a secondary harvesting p

64 early does not derive its input from classic EMDs.

65 (23.53%); CAF + CM (52.94%), and CAF + CM + EMD (51.47%) (P <0.05).

66 (n = 17), CAF + EMD (n = 17), and CAF + CM + EMD (n = 17).

67 (n = 17); CAF + EMD (n = 17), or CAF + CM + EMD (n = 17).

68 cant for CAF + CM, CAF + EMD, and CAF + CM + EMD (P <0.05).

69 ted with CAF + CM, CAF + EMD, and CAF + CM + EMD.

70 liquid carrier system for EMD, used to coat EMD, may be advantageous for better surface coating.

71 results of this study suggest that combining EMD and SPPF in the treatment of suprabony defects may l

72 ial than the commercially available complete EMD compound and that the mechanism of action, in part,

73 an those of the other pools and the complete EMD compound and was concentration dependent.

74 Six of these pools, along with the complete EMD unfractionated compound and positive and negative co

75 Conversely, EMD did not induce MMP-8 secretion from PMNs.

76 of young adults-the Eccentric Muscle Damage (EMD; n = 156) cohort and the Functional Single Nucleotid

77 Using empirical mode decomposition (EMD), which allows measurement of narrow-band changes in

78 the distribution of electromechanical delay (EMD), the time interval between local depolarization and

79 Enamel matrix derivative (EMD) and collagen membranes (CMs) are simultaneously app

80 us combinations of enamel matrix derivative (EMD) and grafting materials has been shown to promote pe

81 the combination of enamel matrix derivative (EMD) and natural bone mineral (NBM) with and without add

82 Enamel matrix derivative (EMD) and recombinant human platelet-derived growth facto

83 are the effects of enamel matrix derivative (EMD) associated with a hydroxyapatite and beta-tricalciu

84 e effectiveness of enamel matrix derivative (EMD) associated with a simplified papilla preservation f

85 en matrix (CM) and enamel matrix derivative (EMD) characteristics, it is suggested that their combina

86 The enamel matrix derivative (EMD) contains hundreds of peptides in different levels o

87 The use of an enamel matrix derivative (EMD) has been shown to enhance periodontal regeneration

88 clinical use of an enamel matrix derivative (EMD) has been shown to promote formation of new cementum

89 eriodontal therapy enamel matrix derivative (EMD) has been successfully used for tissue regeneration

90 Enamel matrix derivative (EMD) has been used in periodontal regenerative procedure

91 Although enamel matrix derivative (EMD) has been used to promote periodontal regeneration,

92 Although enamel matrix derivative (EMD) has demonstrated the ability to promote angiogenesi

93 matrix (CM) and/or enamel matrix derivative (EMD) in combination with a coronally advanced flap (CAF)

94 ix graft (ADMG) or enamel matrix derivative (EMD) in conjunction with a coronally advanced flap (CAF)

95 Enamel matrix derivative (EMD) is commonly used in periodontal therapy.

96 Enamel matrix derivative (EMD) is suggested to stimulate transforming growth facto

97 mine the impact of enamel matrix derivative (EMD) on superoxide (O(2)(-)) generation, chemotaxis, and

98 gical debridement, enamel matrix derivative (EMD) was placed into the bony defect.

99 Use of enamel matrix derivative (EMD) when dealing with non-contained defects may be limi

100 regeneration (GTR)/enamel matrix derivative (EMD) with and without laser treatment, the WMD of PD was

101 t a combination of enamel matrix derivative (EMD) with demineralized freeze-dried bone allograft (DFD

102 efficacy of using enamel matrix derivative (EMD) with demineralized freeze-dried bone allograft (DFD

103 on treatments with enamel matrix derivative (EMD), a commercial formulation of EMPs, suggest that it

104 uate the effect of enamel matrix derivative (EMD), tyrosine-rich amelogenin peptide (TRAP), and a syn

105 fects treated with enamel matrix derivative (EMD).

106 een obtained using enamel matrix derivative (EMD).

107 ed with an enamel matrix protein derivative (EMD) combined with either a natural bone mineral (NBM) o

108 ith either enamel matrix protein derivative (EMD) or collagen membrane (CM).

109 rotein [BMP]-2 and enamel matrix derivative [EMD]) were compared to a control coculture that was unst

110 Enamel matrix derivatives (EMDs) have been used in periodontal regenerative procedu

111 Enamel matrix derivatives (EMDs) have demonstrated proof-of-principle that periodon

112 ubstrate for the elementary motion detector (EMD) [2].

113 , via so-called elementary motion detectors (EMDs).

114 estrous phases (estrus/metaestrus/diestrus (EMD)) froze more during extinction retrieval than those

115 under both conditions, the three-dimensional EMD distribution is nonuniform.

116 ving rise to heterogeneous three-dimensional EMD distributions.

117 Purpose Extramedullary disease (EMD) at diagnosis in patients with acute myeloid leukemi

118 (n = 40) an electronic medication dispenser (EMD).

119 10 years and between treatment groups (i.e., EMD versus CTG) at the same time points were examined.

120 and root planing and treated with 24% EDTA, EMD, and/or human blood in six clinically related settin

121 andomly treated with a combination of either EMD + NBM or EMD + beta-TCP.

122 ent study, regenerative therapy using either EMD + DBBM or CM + DBBM yielded comparable clinical outc

123 one grafts after surface coating with either EMD (as a liquid formulation) or EMD (as a gel formulati

124 llow-up investigation, treatment with either EMD + CAF or CTG + CAF for Miller Class I and II GR defe

125 ndomly assigned to the treatment with either EMD + DBBM (test: n = 20) or CM + DBBM (control: n = 20)

126 urgery of deep intrabony defects with either EMD + NBM + PRP or EMD + NBM.

127 bony defect was randomly treated with either EMD + NBM + PRP or EMD + NBM.

128 ium phosphate (CaP), were coated with either EMD liquid or EMD gel.

129 f the defects amounted to 6.1 +/- 1.9 mm for EMD + DBBM and 6.0 +/- 1.9 mm for CM + DBBM sites (P = 0

130 he potential for a liquid carrier system for EMD, used to coat EMD, may be advantageous for better su

131 lonal antibody was loaded into the Fractogel EMD SO(3) (M) cation exchanger at 2 mS/cm or 10 mS/cm.

132 lonal antibody was loaded onto the Fractogel EMD SO3 (M) cation exchanger at either pH 5 or pH 4.

133 purified 5-kDa protein fraction derived from EMD were also tested at various amounts ranging from 15

134 phosphate/hydroxyapatite graft (BONE group), EMD+BONE, or EMD alone.

135 In GTR/EMD with and without laser treatment, the WMD of CAL gai

136 e WMD of PD was negligible; however, the GTR/EMD group showed better outcomes (P = 0.005) than the la

137 However, EMD and BONE+EMD groups demonstrated more long-term redu

138 11 clinical trials, were studied to identify EMD, as defined by physical examination, laboratory find

139 In EMD-treated intrabony defects, baseline PD predicts both

140 en freezing and IL-BLA circuit activation in EMD animals, and a negative correlation in PRO animals.

141 ntly higher in G1 when compared to G2 and in EMD-treated sites of both groups.

142 Leukocyte infiltration was decreased in EMD-treated wounds at day 1 (P = 0.03), and P2 and TRAP

143 tive osteoclasts was significantly higher in EMD-treated sites of G1.

144 inction retrieval in PRO and enhancing it in EMD.

145 material before mixing with EMD may inhibit EMD adsorption.

146 The results provide novel insights into EMD-CTGF interaction in PDL cells.

147 er-shortening onset, and results in a longer EMD, giving rise to heterogeneous three-dimensional EMD

148 ertebrate visual cortex the output from many EMDs is pooled in neurons sensitive to wide-field optic

149 The small molecule EMD 57033 has been shown to stimulate the actomyosin ATP

150 ured in elementary motion-detecting neurons (EMDs).

151 Non-EMD motion processing may therefore serve an important f

152 The non-EMD driven flicker sensitivity leads to strong, nondirec

153 ns from blood samples altered the ability of EMD to adsorb to root surfaces on human teeth.

154 related settings to determine the ability of EMD to adsorb to root surfaces.

155 aim of this study is to test the ability of EMD to adsorb to the surface of DFDBA particles and dete

156 beta receptor I kinase-dependent activity of EMD and make it available for potential target cells.

157 Addition of EMD 57033 to heat-inactivated beta-cardiac myosin is fol

158 The results suggest that the addition of EMD to DFDBA particles may influence periodontal regener

159 ntal surgeries to allow better adsorption of EMD to root surfaces.

160 d controversial results after application of EMD combined with different types of bone grafting mater

161 rect diagnosis, or no adequate assessment of EMD at baseline.

162 efects after treatment with a combination of EMD and biphasic calcium phosphate (BC) or EMD alone.

163 n assay demonstrated that the combination of EMD liquid + NBM and EMD liquid + DFDBA adsorbed higher

164 ith this information, selected components of EMD can now be formulated for optimal osteo- and angio-g

165 e present study was to compare the effect of EMD and its fractions on the cytokine profiles from huma

166 DFDBA particles and determine the effect of EMD coating on downstream cellular pathways such as adhe

167 resence of blood and determine the effect of EMD coating to NBM particles on downstream cellular path

168 To explore the effects of EMD and TGF-beta1 on CTGF expression, cells were treated

169 This study explores the effects of EMD and TGF-beta1 on CTGF in periodontal ligament (PDL)

170 This study examines the in vivo effects of EMD on healing of an oral mucosa surgical wound in rats.

171 igate proliferative and cytotoxic effects of EMD on oral epithelial cells and their possible influenc

172 Effects of EMD on oral epithelial cells are of crucial importance i

173 Cytotoxic effects of EMD treatment were sampled by lactate dehydrogenase rele

174 c analysis was used to study the fraction of EMD proteins binding to collagen.

175 e the incidence and clinical implications of EMD.

176 The overall incidence of EMD was 23.7%.

177 lood demonstrated a consistent even layer of EMD adsorption to the root surface.

178 In the presence of EMD 57033, ATP hydrolysis, coupling between actin and nu

179 risk and WBC count, neither the presence of EMD nor the number of specific sites of EMD were indepen

180 tic factors, irrespective of the presence of EMD.

181 MN in vitro to better understand the role of EMD in surgical wound healing.

182 Most patients (65.3%) had only one site of EMD, 20.9% had two sites, 9.5% had three sites, and 3.4%

183 e of EMD nor the number of specific sites of EMD were independently prognostic.

184 , in certain clinical situations, the use of EMD alone may not be sufficient to prevent flap collapse

185 The use of EMD in combination with a coronally advanced flap compar

186 The use of EMD in furcations (2.6 +/- 1.8 mm) gave significantly mo

187 The use of EMD in furcations will give more reduction in horizontal

188 he question of whether the additional use of EMD in periodontal therapy is more effective compared wi

189 re search in MEDLINE (PubMed) for the use of EMD in periodontal treatment was performed up to May 201

190 The use of EMD in treatment of intrabony defects, furcations, and r

191 e treatment of intrabony defects, the use of EMD is superior to control treatments but as effective a

192 The additional use of EMD with a coronally advanced flap for recession coverag

193 fferent quadrants, were each treated by OFD, EMD, or EMD + HA/beta-TCP in each defect.

194 higher osteoblast and PDL cell attachment on EMD-coated surfaces when compared with control and blood

195 in, in osteoblasts and PDL cells cultured on EMD-coated DFDBA particles at 3, 7, and 14 days.

196 OC, in osteoblasts and PDL cells cultured on EMD-coated NBM particles.

197 evaluate the effect of blood interactions on EMD adsorption to root surfaces mimicking various clinic

198 K11, one HEXB, three DBT, one HRPT1, and one EMD cases).

199 s provide the best outcomes, whereas ADMG or EMD in conjunction with CAF may be used as an alternativ

200 advanced flap (CAF) combined with CM and/or EMD.

201 >/=6 mm were randomly treated with EMD/BC or EMD alone.

202 f EMD and biphasic calcium phosphate (BC) or EMD alone.

203 roxyapatite graft (BONE group), EMD+BONE, or EMD alone.

204 lass I and II GR defects treated with CTG or EMD, both in combination with coronally advanced flap (C

205 quadrants, were each treated by OFD, EMD, or EMD + HA/beta-TCP in each defect.

206 with either EMD (as a liquid formulation) or EMD (as a gel formulation).

207 (CaP), were coated with either EMD liquid or EMD gel.

208 with regenerative surgery using EMD + NBM or EMD + beta-TCP can be maintained over a period of 10 yea

209 ed with a combination of either EMD + NBM or EMD + beta-TCP.

210 abony defects with either EMD + NBM + PRP or EMD + NBM.

211 domly treated with either EMD + NBM + PRP or EMD + NBM.

212 llocated into two intervention groups: ortho/EMD/DFDBA (n = 24) and EMD/DFDBA (n = 23).

213 The ortho/EMD/DFDBA group had statistically significant open probi

214 Furthermore, prelayering EMD induced an increase of TER of primary cells.

215 t protein pools from a commercially produced EMD were collected based on molecular weight.

216 rafts, and enamel matrix derivative protein (EMD) procedures were superior in achieving CRC when comp

217 PPF technique; 25 participants also received EMD (test group) and 25 patients underwent flap surgery

218 ler Class I and II GR, each patient received EMD+CAF for three teeth and CTG+CAF for one tooth for ro

219 ses to pairwise correlations in Drosophila's EMD neurons, T4 and T5.

220 These results suggest EMD may enhance barrier function.

221 ness flaps were raised, and, after suturing, EMD was injected underneath the soft tissues on one side

222 atomical substrates for the two arms of a T5 EMD circuit; Tm1 and Tm2 provide a second.

223 In the present study, the aim is to test EMD adsorption to the surface of natural bone mineral (N

224 It was demonstrated that EMD and pool 7 induced phospho-SMAD, osterix, and VEGF-A

225 onclusion This large study demonstrates that EMD at any site is common but is not an independent prog

226 Here, we show that EMD 57033 binds to an allosteric pocket in the myosin mo

227 The in vitro study showed that EMD and its high and low molecular weight fractions redu

228 In vitro studies showed that EMD stimulates various cellular effects, which could pot

229 Together, the data suggest that EMD enhances wound healing and reduces inflammation.

230 lucidated, but in vitro studies suggest that EMD may enhance healing, in part, by stimulating angioge

231 usly reported in vitro studies, suggest that EMD may increase angiogenesis directly and/or indirectly

232 The EMD is associated with high compliance, and there are al

233 The EMD, which was used for the 1-year study period, recorde

234 Although the EMD has been the preferred model for more than 50 years,

235 In the EMD + beta-TCP group three defects had lost 2 mm, wherea

236 82% (i.e., nine of 11) of the defects in the EMD + beta-TCP group.

237 4% (i.e., seven of 11) of the defects in the EMD + NBM group and in 82% (i.e., nine of 11) of the def

238 At 10 years two defects in the EMD + NBM group had lost 2 mm, whereas two other defects

239 In the EMD + NBM group, one defect lost 2 mm and four other def

240 Four sites in the EMD + PRP + NBM group lost 1 mm of the CAL gained at 1 y

241 BC group and 3.30 +/- 1.89 mm (48.7%) in the EMD group were achieved.

242 BC group and 2.65 +/- 2.18 mm (36.2%) in the EMD group were obtained.

243 s from baseline values, including wKT in the EMD group, which at 1 year was not significantly improve

244 Men in the EMD study with two copies of the protective allele showe

245 CAL gain of 2.38 +/- 2.17 mm (24.9%) in the EMD/BC group and 2.65 +/- 2.18 mm (36.2%) in the EMD gro

246 eductions of 3.14 +/- 1.95 mm (39.6%) in the EMD/BC group and 3.30 +/- 1.89 mm (48.7%) in the EMD gro

247 el, 3.18 to 4.36; P = 0.036) compared to the EMD/DFDBA group (95% confidence level, 2.26 to 3.24) in

248 At 12 and 24 months after treatment, the EMD + HA/beta-TCP group showed significantly greater PD

249 th the soft tissues on one side, whereas the EMD vehicle was injected in the contralateral side.

250 nd in vivo, the specific elements within the EMD compound responsible for these effects remain unknow

251 The pattern of neural responses in the EMDs was inconsistent with one classical model of motion

252 glycopeptide enrichment kit offered through EMD Millipore.

253 Thus, EMD 57033 displays a much wider spectrum of activities t

254 available collagen products were exposed to EMD or recombinant TGF-beta1, followed by vigorous washi

255 ricalcium phosphate (HA/beta-TCP) implant to EMD alone and to open-flap debridement (OFD) when surgic

256 n matrix to adsorb the activity intrinsic to EMD that provokes transforming growth factor (TGF)-beta

257 nts obtained with regenerative surgery using EMD + NBM or EMD + beta-TCP can be maintained over a per

258 and proliferation in all samples coated with EMD (irrespective of EDTA) when compared to samples cont

259 Grafting materials coated with EMD gel adsorbed more frequently to the exterior of graf

260 Samples coated with EMD lacking blood demonstrated a consistent even layer o

261 osed, using a bone graft in combination with EMD to avoid collapse of the flap into the bony defect d

262 during periodontal surgery may compete with EMD adsorption to root surfaces.

263 The treatment of intrabony defects with EMD showed a significant additional gain in CAL of 1.30

264 ment of non-contained infrabony defects with EMD, with or without BC, resulted in statistically signi

265 r and more sustained O(2)(-) generation with EMD.

266 nct of an HA/beta-TCP composite implant with EMD may improve the clinical and radiographic outcomes o

267 Precoating of inserts with EMD induced a significant increase of TER and barrier fu

268 of the grafting material before mixing with EMD may inhibit EMD adsorption.

269 root resorption and ankylosis was noted with EMD+CAF.

270 appear to improve the results obtained with EMD + NBM.

271 Treatment decisions for patients with EMD should be made on the basis of recognized AML progno

272 DFDBA particles were precoated with EMD or human blood and analyzed for protein adsorption p

273 ium or added to wells/inserts precoated with EMD.

274 Acute Ca sensitization with EMD 57033 mimicked the effects of Ca-sensitizing TnT mut

275 cles were precoated in various settings with EMD or human blood and analyzed for protein adsorption p

276 ntly elevated when PMNs were stimulated with EMD (200 mug/mL) (P <0.01).

277 and the cocultures that were stimulated with EMD and BMP-2 achieved significantly higher levels of th

278 Human PDL cells were stimulated with EMD.

279 Combined stimulation with EMD plus fMLP resulted in significantly higher chemotaxi

280 The sites treated with EMD + beta-TCP showed a mean CAL change from 9.1 +/- 1.6

281 The mean CAL gain at sites treated with EMD + DBBM was not statistically significantly different

282 n 83% (10 of 12) of the defects treated with EMD + NBM + PRP and in 100% (all 12) of the defects trea

283 The sites treated with EMD + NBM + PRP demonstrated a mean CAL change from 10.5

284 The defects treated with EMD + NBM demonstrated a mean CAL change from 8.9 +/- 1.

285 in 100% (all 12) of the defects treated with EMD + NBM.

286 frabony defects were surgically treated with EMD and DFDBA 4 weeks before application of orthodontic

287 CAM treated with EMD displayed moderate vascularity as indicated by a max

288 imary keratinocytes were either treated with EMD dissolved in culture medium or added to wells/insert

289 Seven of the nine teeth treated with EMD+CAF demonstrated varying degrees of periodontal rege

290 a 2- or 3-wall intrabony defect treated with EMD, were included.

291 groups: non-treated control and treated with EMD.

292 oups: non-treated (control) and treated with EMD.

293 epth (PD) >/=6 mm were randomly treated with EMD/BC or EMD alone.

294 of periodontal defects after treatment with EMD under the influence of CS in the rat model.

295 of periodontal defects after treatment with EMD under the influence of DM.

296 periodontal microbiome after treatment with EMD using a deep-sequencing approach.

297 ution to cells with precoating of wells with EMD.

298 rated by precoating culture plate wells with EMD.

299 ar-weight protein pools (7 to 17 kDa) within EMD have greater osteoinductive potential than the comme

300 y was the difference in wKT found at 1 year (EMD, 3.00 mm; CTG, 3.89 mm; P = 0.031).